| Q89544041 | A Prospective Longitudinal Investigation of Cortical Thickness and Gyrification in Schizophrenia |
| Q38629163 | A neurodevelopment and neuroplasticity-based framework for early intervention in psychotic disorders. |
| Q36382573 | Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone |
| Q37162805 | Adjusting for matching and covariates in linear discriminant analysis |
| Q37181862 | Age and diffusion tensor anisotropy in adolescent and adult patients with schizophrenia |
| Q42278927 | Age-related increase in the number of oligodendrocytes is dysregulated in schizophrenia and mood disorders |
| Q35306297 | Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients |
| Q34700949 | Altered cortical thickness related to clinical severity but not the untreated disease duration in schizophrenia. |
| Q36994983 | An automated segmentation methodology for quantifying immunoreactive puncta number and fluorescence intensity in tissue sections |
| Q45290173 | Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease |
| Q38830416 | Antipsychotic drugs in Huntington's disease. |
| Q57825253 | Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective |
| Q30394550 | Auditory verbal hallucinations and the interhemispheric auditory pathway in chronic schizophrenia |
| Q35852767 | Autophagy inhibition uncovers the neurotoxic action of the antipsychotic drug olanzapine. |
| Q22252332 | Bipolar disorder and mechanisms of action of mood stabilizers |
| Q33948574 | Brain tissue changes and antipsychotic medication |
| Q48653346 | Brain volume changes in schizophrenia: how do they arise? What do they mean? |
| Q45071432 | Can long-term treatment with antipsychotic drugs lead to structural brain damage? Against |
| Q33852998 | Cerebral white matter abnormalities and their associations with negative but not positive symptoms of schizophrenia |
| Q37049223 | Cerebral white matter structure is associated with DSM-5 schizophrenia symptom dimensions |
| Q37412453 | Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss |
| Q35001561 | Cingulum bundle integrity associated with delusions of control in schizophrenia: Preliminary evidence from diffusion-tensor tractography |
| Q52356865 | Clinical Findings Documenting Cellular and Molecular Abnormalities of Glia in Depressive Disorders. |
| Q24616310 | Corpus callosum abnormalities and their association with psychotic symptoms in patients with schizophrenia |
| Q46461905 | Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders |
| Q34339682 | Decrease in temporal gyrus gray matter volume in first-episode, early onset schizophrenia: an MRI study |
| Q37124922 | Decreased Oligodendrocyte and Neuron Number in Anterior Hippocampal Areas and the Entire Hippocampus in Schizophrenia: A Stereological Postmortem Study |
| Q33758561 | Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome |
| Q37804646 | Design-based stereology: introduction to basic concepts and practical approaches for estimation of cell number |
| Q89891607 | Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial |
| Q30485576 | Effects of mental illness and aging in two thalamic nuclei |
| Q37251894 | Electrophysiological and diffusion tensor imaging evidence of delayed corollary discharges in patients with schizophrenia |
| Q34429141 | Evidence for morphological alterations in prefrontal white matter glia in schizophrenia and bipolar disorder |
| Q39248594 | Extrastriatal dopamine D2/3 receptors and cortical grey matter volumes in antipsychotic-naïve schizophrenia patients before and after initial antipsychotic treatment |
| Q38396145 | Fiber geometry in the corpus callosum in schizophrenia: evidence for transcallosal misconnection |
| Q98177477 | Free Thyroxine Concentrations Moderate the Response to a Cognitive Remediation Therapy in People With Early Psychosis: A Pilot Randomized Clinical Trial |
| Q37546096 | Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy |
| Q42961696 | Haloperidol promotes proliferation but inhibits differentiation in rat oligodendrocyte progenitor cell cultures |
| Q38060893 | Improving myelin/oligodendrocyte-related dysfunction: a new mechanism of antipsychotics in the treatment of schizophrenia? |
| Q40277970 | In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia |
| Q42774951 | Increased expression of astrocyte markers in schizophrenia: Association with neuroinflammation. |
| Q40369343 | Increased fractional anisotropy in cerebellum in obsessive-compulsive disorder |
| Q34738782 | Levels of S100B are raised in female patients with schizophrenia. |
| Q37800531 | Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia |
| Q35211261 | Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory |
| Q33814201 | Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. |
| Q58698080 | Maximizing Explanatory Power in Stereological Data Collection: A Protocol for Reliably Integrating Optical Fractionator and Multiple Immunofluorescence Techniques |
| Q35019147 | Multimodal neuroimaging of frontal white matter microstructure in early phase schizophrenia: the impact of early adolescent cannabis use |
| Q48663888 | Myelination deficits in schizophrenia: evidence from diffusion tensor imaging |
| Q57473376 | N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial |
| Q34509385 | NeuN+ neuronal nuclei in non-human primate prefrontal cortex and subcortical white matter after clozapine exposure |
| Q37981491 | Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments |
| Q21245244 | Neuroinflammation and psychiatric illness |
| Q34111775 | Neuroprogressive effects of lifetime illness duration in older adults with bipolar disorder |
| Q44938201 | Obsessional jealousy: unusual presentation |
| Q30405077 | Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia |
| Q39646600 | Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness |
| Q34807152 | Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia |
| Q34274859 | Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents |
| Q30422050 | Postmortem brain: an underutilized substrate for studying severe mental illness |
| Q34427616 | Predicting inter-hemispheric transfer time from the diffusion properties of the corpus callosum in healthy individuals and schizophrenia patients: a combined ERP and DTI study |
| Q30529640 | Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia |
| Q36395044 | Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia |
| Q34351095 | Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. |
| Q39590683 | Protective effects of haloperidol and clozapine on energy-deprived OLN-93 oligodendrocytes. |
| Q57300096 | Putative Astroglial Dysfunction in Schizophrenia: A Meta-Analysis of H-MRS Studies of Medial Prefrontal Myo-Inositol |
| Q37417633 | Pyramidal neuron number in layer 3 of primary auditory cortex of subjects with schizophrenia. |
| Q90221116 | Radiation Induced Demyelination in Cervical Spinal Cord of the Head and Neck Cancer Patients after Receiving Radiotherapy |
| Q36580028 | Reciprocal Alterations in Regulator of G Protein Signaling 4 and microRNA16 in Schizophrenia |
| Q24658134 | Reduced dendritic spine density in auditory cortex of subjects with schizophrenia |
| Q48277381 | Reduced density of ADAM 12-immunoreactive oligodendrocytes in the anterior cingulate white matter of patients with schizophrenia |
| Q52690104 | Reduced oligodendrocyte density in layer 5 of the prefrontal cortex in schizophrenia. |
| Q48189224 | Relationships between corpus callosum and language lateralization in patients with schizophrenia and bipolar disorders |
| Q92282698 | Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration |
| Q37130617 | Spatial distribution and density of oligodendrocytes in the cingulum bundle are unaltered in schizophrenia |
| Q34279949 | Stereological Approaches to Identifying Neuropathology in Psychosis |
| Q36117393 | Structural abnormalities in the cuneus associated with Herpes Simplex Virus (type 1) infection in people at ultra high risk of developing psychosis |
| Q41897023 | Structural basis of the fronto-thalamic dysconnectivity in schizophrenia: A combined DCM-VBM study |
| Q90704624 | Subtle Brain Developmental Abnormalities in the Pathogenesis of Juvenile Myoclonic Epilepsy |
| Q36646844 | Temporal profile of astrocytes and changes of oligodendrocyte-based myelin following middle cerebral artery occlusion in diabetic and non-diabetic rats |
| Q30828492 | Tetramethylpyrazine nitrone, a multifunctional neuroprotective agent for ischemic stroke therapy |
| Q48596750 | The effects of antipsychotics on brain structure: what have we learnt from structural imaging of schizophrenia? |
| Q34581127 | The nature of relapse in schizophrenia |
| Q91049124 | The neuropathology of bipolar disorder: systematic review and meta-analysis |
| Q37230904 | Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain |
| Q37896626 | Understanding aberrant white matter development in schizophrenia: an avenue for therapy? |
| Q60242772 | Veränderungen von Hirnvolumina durch Antipsychotika bei Schizophrenie? |
| Q33703935 | Volume and neuron number of the lateral geniculate nucleus in schizophrenia and mood disorders |
| Q90069453 | White matter abnormalities across the lifespan of schizophrenia: a harmonized multi-site diffusion MRI study |
| Q37705723 | White matter changes associated with antipsychotic treatment in first-episode psychosis |
| Q57502150 | White matter correlates of the disorganized speech dimension in schizophrenia |
| Q36102040 | White matter integrity in individuals at ultra-high risk for psychosis: a systematic review and discussion of the role of polyunsaturated fatty acids. |
| Q34778177 | White matter microstructural abnormalities of the cingulum bundle in youths with 22q11.2 deletion syndrome: associations with medication, neuropsychological function, and prodromal symptoms of psychosis |
| Q34074845 | White matter microstructure in untreated first episode bipolar disorder with psychosis: comparison with schizophrenia |
| Q48148097 | White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment |
| Q87117734 | [Can long-term treatment with antipsychotic drugs lead to structural brain damage? Pro] |
| Q87945859 | [Frontal brain volume reduction due to antipsychotic drugs?] |
| Q45958384 | [Personalised medicine in psychiatry and psychotherapy. A review of the current state-of-the-art in the biomarker-based early recognition of psychoses]. |